Pfizer announced today that the European Commission (EC) has approved its trastuzumab biosimilar, Trazimera, referencing Herceptin, for marketing. The approval makes Trazimera the fourth trastuzumab biosimilar (following Kanjinti, Ontruzant, and Herzuma) to be approved by the EC, and the first approval of an anticancer biosimilar for Pfizer.
Pfizer announced today that the European Commission (EC) has approved its trastuzumab biosimilar, Trazimera, referencing Herceptin, for marketing. The approval makes Trazimera the fourth trastuzumab biosimilar (following Kanjinti, Ontruzant, and Herzuma) to be approved by the EC, and the first approval of an anticancer biosimilar for Pfizer.
Today’s approval allows the drug to be marketed in the 28 member states of the European Union as well as in the European Economic Area. The biosimilar has been approved to treat HER2-positive breast cancer, metastatic gastric cancer, and gastroesophageal junction adenocarcinoma, the same indications as its reference product.
In a statement, Diana Lüftner, Dr med, of the Charité Campus Benjamin Franklin in Berlin, Germany, and member of the presidency of the German Society of Hematology and Medical Oncology, hailed the approval, saying that the biosimilar “has the potential to help many patients with HER2-overexpressing cancers, such as breast and gastric, which can correlate with poor outcomes and aggressive disease. Today’s approval will help enable greater access for patients and physicians across Europe, without compromising on quality, efficacy and safety.”
The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June 2018, which relied on a data package that included results from Pfizer’s phase 3 REFLECTIONS B327-02 study, results of which were presented at the European Society for Medical Oncology conference in 2017. The study, in 707 patients with HER2-positive metastatic breast cancer, found that Pfizer’s biosimilar was similar to EU-licensed trastuzumab in terms of efficacy, safety, immunogenicity, and pharmacokinetics when used as first-line treatment.
While Pfizer has cleared the final regulatory hurdle for its product in the European market, in April 2018, Pfizer received a Complete Response Letter from the FDA for the same molecule. The company says that the FDA highlighted the need for “additional technical information,” and that the agency did not request information related to safety or clinical data submitted in the Biologics License Application. Pfizer indicated that it will work closely with the FDA to address the letter’s contents and that it remains committed to developing the product.
In the United States, only 1 trastuzumab biosimilar, Mylan and Biocon’s Ogivri, has received approval from the FDA. No launch date has been announced for the drug.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
2 Commerce Drive
Cranbury, NJ 08512